Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir

Antimicrob Agents Chemother. 2004 Aug;48(8):2911-7. doi: 10.1128/AAC.48.8.2911-2917.2004.

Abstract

Using measured free fraction and 50% inhibitory concentration (IC50) values for the human immunodeficiency virus protease inhibitors lopinavir (LPV) and ritonavir (RTV) in tissue culture media with various protein concentrations ranging from 5 to 50%, we estimated serum-free IC50 values for each drug. The range of serum-free IC50 values (0.64 to 0.77 ng/ml for LPV and 3.0 to 5.0 ng/ml for RTV) did not exhibit a trend with increasing protein concentrations, despite a 10-fold difference in the free fraction value (0.006 to 0.063) for LPV and a 5-fold difference in the free fraction value (0.013 to 0.057) for RTV. The mean serum-free IC50 by the MTT-MT4 assay (0.69 ng/ml for LPV and 4.0 ng/ml for RTV) may be the most accurate parameter for the estimation of the inhibitory quotient (IQ), a relative measure of in vivo potency defined as the ratio of the minimal free drug concentration in plasma (C(trough,free)) for a specific patient population and the serum-free IC50. Using this approach, we calculated the average IQs for protease inhibitor-naïve patients for LPV and RTV to be 67 and 5.6, respectively.

MeSH terms

  • Algorithms
  • Animals
  • Biological Assay
  • Cattle
  • Chromatography, High Pressure Liquid
  • HIV Protease / metabolism
  • HIV Protease Inhibitors / pharmacokinetics*
  • HIV Protease Inhibitors / pharmacology*
  • Humans
  • Kinetics
  • Lopinavir
  • Protein Binding
  • Pyrimidinones / pharmacokinetics*
  • Pyrimidinones / pharmacology*
  • Ritonavir / pharmacokinetics*
  • Ritonavir / pharmacology*

Substances

  • HIV Protease Inhibitors
  • Pyrimidinones
  • Lopinavir
  • HIV Protease
  • Ritonavir